[1]Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. (2017) 541:321–30.
[2]Karuna Ganesh, Zsofia K Stadler, Andrea Cercek,et al.Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375.
[3]Aaron J Franke, William Paul Skelton,et al.Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.J Natl Cancer Inst.2019 Nov 1;111(11):1131-1141.
[4]Pawel Wrobel, Shahid Ahmed.Current status of immunotherapy in metastatic colorectal cancer.Int J Colorectal Dis.2019 Jan;34(1):13-25.
[5] Sharma P, Hulieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. (2017) 168:707– 23.
[6]Dung T Le, Jennifer N Durham, Kellie N Smith, et al.Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade.Science. 2017 Jul 28;357(6349):409-413.
[7]Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang,et al.Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.Clin Cancer Res.2017 Jun 15;23(12):3012-3024.
[8]Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang,et al.Alteration in TET1 as Potential Biomarker for Immune Checkpoint Blockade in Multiple Cancers. J Immunother Cancer,2019 Oct 17;7(1):264.
[9]Mei Ji, Yan Liu, Qing Li, Xiaodong Li,et al.PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.Cancer Biol Ther.2016 Apr 2;17(4):407-13.
[10]Yuchun Niu, Anqi Lin, Peng Luo,et al.Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.Front Pharmacol. 2020 Aug 12;11:1213.
[11]Jiexia Zhang, Ningning Zhou,Anqi Lin,et al.ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non‑small cell lung cancer.Cancer Immunol Immunother.2020 Jul 11.
[12]Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari,et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types.Nat Genet,2019 Feb;51(2):202-206.
[13]Donavan T Cheng, Talia N Mitchell, Ahmet Zehir, Ronak H Shah, et al.Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.J Mol Diagn.2015 May;17(3):251-64.
[14]Binbin Chen, Michael S Khodadoust, Chih Long Liu, Aaron M Newman, et al.Profiling Tumor Infiltrating Immune Cells With CIBERSORT.Methods Mol Biol. 2018;1711:243-259.
[15]Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012;16(5):284-7.
[16]A S, T P, M VK,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles[J].Proceedings of the National Academy of Sciences of the United States of America,2005,102(43):15545-15550.
[17]Matthew E Ritchie, Belinda Phipson, Di Wu, Yifang Hu,et al.Limma Powers Differential Expression Analyses for RNA-sequencing and Microarray Studies.Nucleic Acids Res. 2015 Apr 20;43(7):e47.
[18]Tsuyoshi Hamada, Thing Rinda Soong, Yohei Masugi,et al.TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.Oncoimmunology.2018 Mar 19;7(7):e1442999.
[19]Mehmet Sitki Copur.Immunotherapy in Colorectal Cancer.Oncology (Williston Park) .2019 Oct 28;33(10):686506.
[20]Malek Kreidieh, Deborah Mukherji,et al.Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.Biomed Res Int.2020 Jan 25;2020:9037217.
[21]Sandip Pravin Patel,Razelle Kurzrock.PD-L1 Expression as a Predictive Biomarkers in Cancer Immunotherapy.Mol Cancer Ther.2015 Apr;14(4):847-56.
[22]Samstein RM, Lee CH, Shoushtari AN. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature genetics. 2019;51(2):202–206.
[23]Stefano Serra, Runjan Chetty.Rnf43.J Clin Pathol.2018 Jan;71(1):1-6.
[24]Peng D, Kryczek I, Nagarsheth N,et al.Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015 Nov 12;527(7577):249-53.
[25]N Auphan, J A DiDonato, C Rosette,et al.Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.Science. 1995 Oct 13;270(5234):286-90.
[26]Hassan Wael, Ryoji Yoshida, Shinji Kudoh,et al.Notch1 Signaling Controls Cell Proliferation, Apoptosis and Differentiation in Lung Carcinoma.Lung Cancer,2014 Aug;85(2):131-40.
[27]Fokhrul Hossain, Amir A Al-Khami, Dorota Wyczechowska,et al.Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.Cancer Immunol Res. 2015 Nov;3(11):1236-47.